Clinical efficacy and safety analysis of CT-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor
Copyright © 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved..
PURPOSE: This study was conducted to evaluate the clinical efficacy and safety of computed tomography (CT)-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor.
METHODS AND MATERIALS: This retrospective study analyzed the data of 30 patients with recurrent and metastatic pelvic malignant tumor who were treated with CT-guided 125I implantation between January 2016 and December 2020. Disease control rate, objective remission rate, overall survival (OS), pain relief rate, quality of life score, and complications were evaluated after the followup.
RESULTS: Median followup was 20.1 (7-30) months. Disease control rate was 86.67% at 6 months. Objective response rates at 1, 3, and 6 months were 36.67%, 60%, and 56.67%, respectively. OS rates at 12 and 24 months were 76.67% (23/30) and 33.33% (10/30), respectively. Progression-free survival rates at 12 and 24 months were 63.33% (19/30) and 33.33% (10/30), respectively. Postoperative pain relief rate was 86.67% (26/30). There were no major bleeding, pelvic abscess, intestinal fistula, intestinal perforation, and other serious complications.
CONCLUSIONS: CT-guided 125I seed implantation in the treatment of patients with pelvic malignant tumor is a simple operation and less traumatic and can improve patients' quality of life and reduce tumor load.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Brachytherapy - 22(2023), 2 vom: 25. März, Seite 132-138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Shenghe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(125)I seed |
|---|
| Anmerkungen: |
Date Completed 10.03.2023 Date Revised 20.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.brachy.2022.10.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350981361 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350981361 | ||
| 003 | DE-627 | ||
| 005 | 20231226050229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.brachy.2022.10.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350981361 | ||
| 035 | |a (NLM)36586808 | ||
| 035 | |a (PII)S1538-4721(22)00330-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Shenghe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical efficacy and safety analysis of CT-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2023 | ||
| 500 | |a Date Revised 20.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: This study was conducted to evaluate the clinical efficacy and safety of computed tomography (CT)-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor | ||
| 520 | |a METHODS AND MATERIALS: This retrospective study analyzed the data of 30 patients with recurrent and metastatic pelvic malignant tumor who were treated with CT-guided 125I implantation between January 2016 and December 2020. Disease control rate, objective remission rate, overall survival (OS), pain relief rate, quality of life score, and complications were evaluated after the followup | ||
| 520 | |a RESULTS: Median followup was 20.1 (7-30) months. Disease control rate was 86.67% at 6 months. Objective response rates at 1, 3, and 6 months were 36.67%, 60%, and 56.67%, respectively. OS rates at 12 and 24 months were 76.67% (23/30) and 33.33% (10/30), respectively. Progression-free survival rates at 12 and 24 months were 63.33% (19/30) and 33.33% (10/30), respectively. Postoperative pain relief rate was 86.67% (26/30). There were no major bleeding, pelvic abscess, intestinal fistula, intestinal perforation, and other serious complications | ||
| 520 | |a CONCLUSIONS: CT-guided 125I seed implantation in the treatment of patients with pelvic malignant tumor is a simple operation and less traumatic and can improve patients' quality of life and reduce tumor load | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (125)I seed | |
| 650 | 4 | |a Clinical efficacy | |
| 650 | 4 | |a Pelvic malignant tumor | |
| 650 | 7 | |a Iodine-125 |2 NLM | |
| 650 | 7 | |a GVO776611R |2 NLM | |
| 700 | 1 | |a Chen, Songbai |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Ruoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chuang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brachytherapy |d 2002 |g 22(2023), 2 vom: 25. März, Seite 132-138 |w (DE-627)NLM147588790 |x 1873-1449 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:2 |g day:25 |g month:03 |g pages:132-138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.brachy.2022.10.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 2 |b 25 |c 03 |h 132-138 | ||